Patents by Inventor James A. Bush

James A. Bush has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antitumor antibiotic kedarcidin
    Patent number: 5001112
    Abstract: Kedarcidin is a protein antitumor antibiotic produced by Streptoalloteichus sp. nov. strain L585-6, ATCC 53650. The antibiotic comprises a non-protein chromophore and a single chain polypeptide having 114 amino acid residues.
    Type: Grant
    Filed: March 17, 1989
    Date of Patent: March 19, 1991
    Assignee: Bristol-Myers Company
    Inventors: Sandra J. Hofstead, James A. Matson, Kin S. Lam, Salvatore Forenza, James A. Bush, Koji Tomita
  • Rigolettone antitumor complex
    Patent number: 4792522
    Abstract: A novel complex designated herein as rigolettone complex is produced by fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems.
    Type: Grant
    Filed: August 22, 1985
    Date of Patent: December 20, 1988
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., Stanley W. Bray, James A. Bush, William T. Bradner
  • Process for producing antitumor antibiotic compound
    Patent number: 4599310
    Abstract: A new cyclic depsipeptide antitumor antibiotic designated herein as sandramycin is produced by fermentation of a new microorganism, Nocardioides sp. strain C49,009, ATCC 39419. Sandramycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: September 25, 1985
    Date of Patent: July 8, 1986
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, James A. Bush
  • Albacarcins V and M
    Patent number: 4598145
    Abstract: Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: April 16, 1984
    Date of Patent: July 1, 1986
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, Robert W. Myllymaki, Terrence W. Doyle, James A. Bush
  • Antitumor antibiotic compound
    Patent number: 4582639
    Abstract: A new cyclic depsipeptide antitumor antibiotic designated herein as sandramycin is produced by fermentation of a new microorganism, Nocardioides sp. strain C49,009, ATCC 39419. Sandramycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: June 18, 1984
    Date of Patent: April 15, 1986
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, James A. Bush
  • Process for producing rebeccamycin
    Patent number: 4552842
    Abstract: A novel antitumor agent designated herein as rebeccamycin is produced by fermentation of Nocardia aerocolonigenes (ATCC 39243). Rebeccamycin and its 5'-N-methyl and 5',2",3",6"-tetraacetate derivatives exhibit activity against experimental animal tumor systems.
    Type: Grant
    Filed: April 13, 1984
    Date of Patent: November 12, 1985
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Terrence W. Doyle
  • Rebeccamycin and process for its preparation
    Patent number: 4487925
    Abstract: A novel antitumor agent designated herein as rebeccamycin is produced by fermentation of Nocardia aerocolonigenes (ATCC 39243). Rebeccamycin and its 5'-N-methyl and 5',2",3",6"-tetraacetate derivatives exhibit activity against experimental animal tumor systems.
    Type: Grant
    Filed: January 28, 1983
    Date of Patent: December 11, 1984
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Terrence W. Doyle
  • Antitumor agents albacarcins V and M
    Patent number: 4461831
    Abstract: Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: August 16, 1982
    Date of Patent: July 24, 1984
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, Robert W. Myllymaki, Terrence W. Doyle, James A. Bush
  • Fermentation process for producing anandimycin
    Patent number: 4360595
    Abstract: A polycyclic antitumor antibiotic designated herein as anandimycin is produced by fermentation of Streptomyces anandii subsp. araffinosus strain C-22,437 (ATCC 31431). Anandimycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: February 20, 1981
    Date of Patent: November 23, 1982
    Assignee: Bristol-Myers Company
    Inventors: David M. Balitz, James A. Bush, Frances A. O'Herron, Donald E. Nettleton, Jr.
  • Fermentation process for making rachelmycin
    Patent number: 4301248
    Abstract: A known antibiotic substance designated herein as rachelmycin is produced by fermentation of Streptomyces sp. strain C-329, variant 70 (ATCC 31128) or Streptomyces anandii subsp. arraffinosus strain C-22, 437 (ATCC 31431). Rachelmycin exhibits both antibiotic and antitumor properties.
    Type: Grant
    Filed: October 6, 1980
    Date of Patent: November 17, 1981
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner
  • Antibiotic complex producing bacterial culture
    Patent number: 4248970
    Abstract: A novel anthracycline antibiotic complex designated herein as figaroic acid complex is produced by fermentation of Streptosporangium sp. strain C-31,751, A.T.C.C. 31129. Figaroic acid complex inhibits the growth of various microorganisms, e.g., Staphylococcus aureus, exhibits phage inducing properties and inhibits the growth of various tumors in rodents, e.g., Sarcoma 180, L-1210 lymphatic leukemia, B-16 melanoma, Walker 256 carcinosarcoma and P-388 lymphatic leukemia.
    Type: Grant
    Filed: May 30, 1978
    Date of Patent: February 3, 1981
    Assignee: Bristol-Myers Company
    Inventors: William T. Bradner, James A. Bush, Donald E. Nettleton, Jr.
  • Antibiotic complex
    Patent number: 4112071
    Abstract: A novel anthracycline antibiotic complex designated herein as figaroic acid complex is produced by fermentation of Streptosporangium sp. strain C-31,751, A.T.C.C. 31129. Figaroic acid complex inhibits the growth of various microorganisms, e.g., Staphylococcus aureus, exhibits phage inducing properties and inhibits the growth of various tumors in rodents, e.g., Sarcoma 180, L-1210 lymphatic leukemia, B-16 melanoma, Walker 256 carcinosarcoma and P-388 lymphatic leukemia.
    Type: Grant
    Filed: September 9, 1977
    Date of Patent: September 5, 1978
    Assignee: Bristol-Myers Company
    Inventors: William T. Bradner, James A. Bush, Donald E. Nettleton, Jr.
  • Antibiotic compounds marcellomycin and musettamycin
    Patent number: 4064014
    Abstract: A novel anthracycline antibiotic complex designated herein as bohemic acid complex is produced by fermentation of Actinosporangium sp. A.T.C.C. 31127. The complex and two bioactive components designated marcellomycin and musettamycin exhibit antibiotic activity and inhibit the growth of various tumor systems in rodents.
    Type: Grant
    Filed: March 23, 1977
    Date of Patent: December 20, 1977
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Richard H. Schreiber
  • Antibiotic compounds marcellomycin and musettamycin
    Patent number: 4039736
    Abstract: A novel anthracycline antibiotic complex designated herein as bohemic acid complex is produced by fermentation of Actinosporangium sp. A.T.C.C. 31127. The complex and two bioactive components designated marcellomycin and musettamycin exhibit antibiotic activity and inhibit the growth of various tumor systems in rodents.
    Type: Grant
    Filed: April 15, 1976
    Date of Patent: August 2, 1977
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., James A. Bush, William T. Bradner, Richard H. Schreiber